Trailing twelve months where a flow is involved, latest reported balance where it is not.
Sales of Generic Pharmaceutical Products is 43% of revenue.
Year to Dec 31, 2025 · $883.4M
Year to Dec 31, 2025 · $883.4M
Year to Dec 31, 2025 · $883.4M
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$1.04BQ3 2026+6.4%
Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.
$249.21MQ3 2026+5.5%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.
$116.84MQ3 2026+7.9%11.2% of revenue
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
11.2%Q3 2026+1.4%
How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.
$205.32MQ3 2026+18.7%
Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.
$5.01Q3 2026+8.2%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
21.83MQ3 2026+0.7%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
15.7xQ3 2026-26.5%
15.7x today · median 68.2x and range 15.7x–143.8x across the points shown, Q4 2016 to Q3 2026 The breaks in the line cover 22 periods with no meaningful multiple — a loss, or earnings so small the ratio says more about the denominator than the price.
Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.
$0.00Q3 2026-100.0%
Cash handed to shareholders. A flat line at zero means the company pays none. Each bar sums the four quarters ending there — a full year, brought up to today.
Everything above comes from ANI Pharmaceuticals, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Share-count jumps we cannot explain: 1,001.38x around Dec 31, 2016. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Gross Profit, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Short-term Borrowings, Change in Customer Advances, Change in Other Operating Capital, and Change in Working Capital. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
ANIP · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$71.44+0.5%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $1.1B to $1.1B for Fiscal year 2026 — up 25.7% on a year earlier